Characterization of buffy coat-derived granulocytes for clinical use: a comparison with granulocyte colony-stimulating factor/dexamethasone-pretreated donor-derived products

A van de Geer, R P Gazendam, A T J Tool, J L van Hamme, D de Korte, T K van den Berg, S S Zeerleder, T W Kuijpers

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

BACKGROUND AND OBJECTIVES: Buffy coat-derived granulocytes have been described as an alternative to the apheresis product from donors pretreated with dexamethasone and granulocyte colony-stimulating factor (G-CSF). The latter is - dependent on the local and national settings - obtained following a demanding and time-consuming procedure, which is undesirable in critically ill septic patients. In contrast, buffy coat-derived products have a large volume and are often heavily contaminated with red cells and platelets. We developed a new pooled buffy coat-derived product with high purity and small volume, and performed a comprehensive functional characterization of these granulocytes.

MATERIALS AND METHODS: We pooled ten buffy coats following the production of platelet concentrates. Saline 0·9% was added to decrease the viscosity and the product was split into plasma, red cells and a 'super' buffy coat. Functional data of the granulocytes were compared to those obtained with granulocytes from healthy controls and G-CSF/dexamethasone-pretreated donors.

RESULTS: Buffy coat-derived granulocytes showed adhesion, chemotaxis, reactive oxygen species production, degranulation, NETosis and in vitro killing of Staphylococcus aureus, Escherichia coli and Aspergillus species comparable to control and G-CSF/dexamethasone-derived granulocytes. Candida killing was superior compared to G-CSF/dexamethasone-derived granulocytes. Immunophenotyping was normal; especially no signs of activation in the buffy coat-derived granulocytes were seen. Viability was reduced. Buffy coats are readily available in the regular blood production process and would take away the concerns around the apheresis product.

CONCLUSION: The product described appears a promising alternative for transfusion purposes.

Original languageEnglish
Pages (from-to)173-182
Number of pages10
JournalVox Sanguinis
Volume112
Issue number2
DOIs
Publication statusPublished - Feb 2017

Cite this

van de Geer, A ; Gazendam, R P ; Tool, A T J ; van Hamme, J L ; de Korte, D ; van den Berg, T K ; Zeerleder, S S ; Kuijpers, T W. / Characterization of buffy coat-derived granulocytes for clinical use : a comparison with granulocyte colony-stimulating factor/dexamethasone-pretreated donor-derived products. In: Vox Sanguinis. 2017 ; Vol. 112, No. 2. pp. 173-182.
@article{ee51ddfd3a8948949f548043f807d282,
title = "Characterization of buffy coat-derived granulocytes for clinical use: a comparison with granulocyte colony-stimulating factor/dexamethasone-pretreated donor-derived products",
abstract = "BACKGROUND AND OBJECTIVES: Buffy coat-derived granulocytes have been described as an alternative to the apheresis product from donors pretreated with dexamethasone and granulocyte colony-stimulating factor (G-CSF). The latter is - dependent on the local and national settings - obtained following a demanding and time-consuming procedure, which is undesirable in critically ill septic patients. In contrast, buffy coat-derived products have a large volume and are often heavily contaminated with red cells and platelets. We developed a new pooled buffy coat-derived product with high purity and small volume, and performed a comprehensive functional characterization of these granulocytes.MATERIALS AND METHODS: We pooled ten buffy coats following the production of platelet concentrates. Saline 0·9{\%} was added to decrease the viscosity and the product was split into plasma, red cells and a 'super' buffy coat. Functional data of the granulocytes were compared to those obtained with granulocytes from healthy controls and G-CSF/dexamethasone-pretreated donors.RESULTS: Buffy coat-derived granulocytes showed adhesion, chemotaxis, reactive oxygen species production, degranulation, NETosis and in vitro killing of Staphylococcus aureus, Escherichia coli and Aspergillus species comparable to control and G-CSF/dexamethasone-derived granulocytes. Candida killing was superior compared to G-CSF/dexamethasone-derived granulocytes. Immunophenotyping was normal; especially no signs of activation in the buffy coat-derived granulocytes were seen. Viability was reduced. Buffy coats are readily available in the regular blood production process and would take away the concerns around the apheresis product.CONCLUSION: The product described appears a promising alternative for transfusion purposes.",
keywords = "Adult, Antigens, Surface, Blood Buffy Coat, Blood Component Removal, Blood Donors, Blood Platelets, Cell Adhesion, Cell Survival, Chemotaxis, Dexamethasone, Granulocyte Colony-Stimulating Factor, Granulocytes, Humans, Immunophenotyping, Leukocyte Count, Male, NADPH Oxidases, Reactive Oxygen Species, Journal Article",
author = "{van de Geer}, A and Gazendam, {R P} and Tool, {A T J} and {van Hamme}, {J L} and {de Korte}, D and {van den Berg}, {T K} and Zeerleder, {S S} and Kuijpers, {T W}",
note = "{\circledC} 2017 International Society of Blood Transfusion.",
year = "2017",
month = "2",
doi = "10.1111/vox.12481",
language = "English",
volume = "112",
pages = "173--182",
journal = "Vox Sanguinis",
issn = "0042-9007",
publisher = "Wiley-Blackwell",
number = "2",

}

Characterization of buffy coat-derived granulocytes for clinical use : a comparison with granulocyte colony-stimulating factor/dexamethasone-pretreated donor-derived products. / van de Geer, A; Gazendam, R P; Tool, A T J; van Hamme, J L; de Korte, D; van den Berg, T K; Zeerleder, S S; Kuijpers, T W.

In: Vox Sanguinis, Vol. 112, No. 2, 02.2017, p. 173-182.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Characterization of buffy coat-derived granulocytes for clinical use

T2 - a comparison with granulocyte colony-stimulating factor/dexamethasone-pretreated donor-derived products

AU - van de Geer, A

AU - Gazendam, R P

AU - Tool, A T J

AU - van Hamme, J L

AU - de Korte, D

AU - van den Berg, T K

AU - Zeerleder, S S

AU - Kuijpers, T W

N1 - © 2017 International Society of Blood Transfusion.

PY - 2017/2

Y1 - 2017/2

N2 - BACKGROUND AND OBJECTIVES: Buffy coat-derived granulocytes have been described as an alternative to the apheresis product from donors pretreated with dexamethasone and granulocyte colony-stimulating factor (G-CSF). The latter is - dependent on the local and national settings - obtained following a demanding and time-consuming procedure, which is undesirable in critically ill septic patients. In contrast, buffy coat-derived products have a large volume and are often heavily contaminated with red cells and platelets. We developed a new pooled buffy coat-derived product with high purity and small volume, and performed a comprehensive functional characterization of these granulocytes.MATERIALS AND METHODS: We pooled ten buffy coats following the production of platelet concentrates. Saline 0·9% was added to decrease the viscosity and the product was split into plasma, red cells and a 'super' buffy coat. Functional data of the granulocytes were compared to those obtained with granulocytes from healthy controls and G-CSF/dexamethasone-pretreated donors.RESULTS: Buffy coat-derived granulocytes showed adhesion, chemotaxis, reactive oxygen species production, degranulation, NETosis and in vitro killing of Staphylococcus aureus, Escherichia coli and Aspergillus species comparable to control and G-CSF/dexamethasone-derived granulocytes. Candida killing was superior compared to G-CSF/dexamethasone-derived granulocytes. Immunophenotyping was normal; especially no signs of activation in the buffy coat-derived granulocytes were seen. Viability was reduced. Buffy coats are readily available in the regular blood production process and would take away the concerns around the apheresis product.CONCLUSION: The product described appears a promising alternative for transfusion purposes.

AB - BACKGROUND AND OBJECTIVES: Buffy coat-derived granulocytes have been described as an alternative to the apheresis product from donors pretreated with dexamethasone and granulocyte colony-stimulating factor (G-CSF). The latter is - dependent on the local and national settings - obtained following a demanding and time-consuming procedure, which is undesirable in critically ill septic patients. In contrast, buffy coat-derived products have a large volume and are often heavily contaminated with red cells and platelets. We developed a new pooled buffy coat-derived product with high purity and small volume, and performed a comprehensive functional characterization of these granulocytes.MATERIALS AND METHODS: We pooled ten buffy coats following the production of platelet concentrates. Saline 0·9% was added to decrease the viscosity and the product was split into plasma, red cells and a 'super' buffy coat. Functional data of the granulocytes were compared to those obtained with granulocytes from healthy controls and G-CSF/dexamethasone-pretreated donors.RESULTS: Buffy coat-derived granulocytes showed adhesion, chemotaxis, reactive oxygen species production, degranulation, NETosis and in vitro killing of Staphylococcus aureus, Escherichia coli and Aspergillus species comparable to control and G-CSF/dexamethasone-derived granulocytes. Candida killing was superior compared to G-CSF/dexamethasone-derived granulocytes. Immunophenotyping was normal; especially no signs of activation in the buffy coat-derived granulocytes were seen. Viability was reduced. Buffy coats are readily available in the regular blood production process and would take away the concerns around the apheresis product.CONCLUSION: The product described appears a promising alternative for transfusion purposes.

KW - Adult

KW - Antigens, Surface

KW - Blood Buffy Coat

KW - Blood Component Removal

KW - Blood Donors

KW - Blood Platelets

KW - Cell Adhesion

KW - Cell Survival

KW - Chemotaxis

KW - Dexamethasone

KW - Granulocyte Colony-Stimulating Factor

KW - Granulocytes

KW - Humans

KW - Immunophenotyping

KW - Leukocyte Count

KW - Male

KW - NADPH Oxidases

KW - Reactive Oxygen Species

KW - Journal Article

U2 - 10.1111/vox.12481

DO - 10.1111/vox.12481

M3 - Article

VL - 112

SP - 173

EP - 182

JO - Vox Sanguinis

JF - Vox Sanguinis

SN - 0042-9007

IS - 2

ER -